The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
Abstract
Purpose: The RET fusion gene has been recently described in a subset of non–small-cell lung cancers (NSCLCs). Because we have limited knowledge about these tumors, this study was aimed at determining the clinicopathologic characteristics of patients with NSCLC harboring the RET fusion gene. Patients and Methods: We examined the RET fusion gene in 936 patients with surgically resected NSCLC using a reverse transcriptase polymerase chain reaction (PCR) plus quantitative real-time PCR strategy, with validation using immunohistochemical and fluorescent in situ hybridization assays. A subset of 633 lung adenocarcinomas was also studied for EGFR, KRAS, HER2, and BRAF mutations, as well as ALK rearrangements. Patient characteristics, including age, sex, smoking history, stage, grade, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of subtypes of lung adenocarcinoma, and relapse-free survival, were collected. Results: Of 936 patients with NSCLC, the RET fusion gene was exclusively detected in 13 patients (11 of 633 patients with adenocarcinomas and two of 24 patients with adenosquamous cell carcinomas). Of the 13 patients, nine patients had KIF5B-RET, three patients had CCDC6-RET, and one patient had a novel NCOA4-RET fusion. Patients with lung adenocarcinomas with RET fusion gene had more poorly differentiated tumors (63.6%; P = .029 for RET v ALK, P = .007 for RET v EGFR), with a tendency to be younger (≤ 60 years; 72.7%) and never-smokers (81.8%) and to have solid subtype (63.6%) and a smaller tumor (≤ 3 cm) with N2 disease (54.4%). The median relapse-free survival was 20.9 months. Conclusion: RET fusion occurs in 1.4% of NSCLCs and 1.7% of lung adenocarcinomas and has identifiable clinicopathologic characteristics, warranting further clinical consideration and targeted therapy investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Self-citationThe impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Molecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Ports, G., Fusco, A., & Vecchiot, G. (1990) · Cell · doi:10.1016/0092-8674(90)90659-3 · Cited by 959
Shaw, A. T., Yeap, B. Y., Solomon, B. J., Riely, G. J., Gainor, J., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S.-H. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 899
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2673 · Cited by 869
KIF5B-RET fusions in lung adenocarcinoma
Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2644 · Cited by 834
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717
Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Muñoz, H., & Fagin, J. A. (1997) · PubMed · Cited by 666
Carlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., & Santoro, M. M. (2002) · PubMed · Cited by 569
Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, S., Bleazard, T., Won, J.-K., Kim, Y. T., Kim, J.-I., Kang, J.-H., & Seo, J.-S. (2012) · Genome Research · doi:10.1101/gr.133645.111 · Cited by 484
Mino-Kenudson, M., Chirieac, L. R., Law, K., Hornick, J. L., Lindeman, N., Mark, E. J., Cohen, D. W., Johnson, B. E., Jänne, P. A., Iafrate, A. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2845 · Cited by 423
Santoro, M. M., Dathan, N. A., Berlingieri, M. T., Bongarzone, I., Paulin, C., Grieco, M., Pierotti, M. A., Vecchio, G., & Fusco, A. (1994) · PubMed · Cited by 366
RET Proto-Oncogene in the Development of Human Cancer
Eng, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.380 · Cited by 339
Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 335
Self-citationComprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas
Yoshida, A., Tsuta, K., Nakamura, H., Kohno, T., Takahashi, F., Asamura, H., Sekine, I., Fukayama, M., Shibata, T., Furuta, K., et al. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182233e06 · Cited by 280
Yi, E. S., Boland, J. M., Maleszewski, J. J., Roden, A. C., Oliveira, A. M., Aubry, M.-C., Erickson-Johnson, M. R., Caron, B. L., Li, Y., Tang, H., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318209edb9 · Cited by 263
Self-citationThe RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
Powell, D. J., Russell, J. P., Nibu, K., Li, G., Rhee, E. N., Liao, M., Goldstein, M., Keane, W. M., Santoro, M. M., Fusco, A., et al. (1998) · PubMed · Cited by 255
RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis
Ciampi, R., & Nikiforov, Y. E. (2007) · Endocrinology · doi:10.1210/en.2006-0921 · Cited by 241
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
Li, C., Fang, R., Sun, Y., Han, X., Li, F., Gao, B., Iafrate, A. J., Liu, X.-Y., Pao, W., Chen, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028204 · Cited by 230
Self-citationZhang, Y., Sun, Y., Pan, Y., Li, C., Shen, L., Li, Y., Luo, X., Ye, T., Wang, R., Hu, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2511 · Cited by 176
Self-citationCrizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?
Antoniu, S. A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.550880 · Cited by 159
Targeting RET Receptor Tyrosine Kinase Activation in Cancer
Phay, J. E., & Shah, M. H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0786 · Cited by 150
RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint
Marotta, V., Guerra, A., Sapio, M. R., & Vitale, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0499 · Cited by 101
RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer
Blaugrund, J. E., Johns, M. M. E., Eby, Y. J., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.10.1895 · Cited by 84
Li, F., Feng, Y., Fang, R., Fang, Z., Xia, J., Han, X., Liu, X., Chen, H., Liu, H., & Ji, H. (2012) · Cell Research · doi:10.1038/cr.2012.27 · Cited by 79
Self-citationMutation-associated fusion cancer genes in solid tumors
Kaye, F. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0135 · Cited by 61
(2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318215ba35 · Cited by 30
Cited by
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 936
Metadata
- Authors
- Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., Li, F., Lu, Y., Lu, Q., Xu, J., Garfield, D., Shen, L., Ji, H., Pao, W., Sun, Y., & Chen, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-12-10
- Volume
- 30
- Issue
- 35
- Pages
- 4352-4359
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168404690
- Cited by
- 546
- References
- 36
- FWCI
- 32.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.